NASDAQ
NEO

NeoGenomics Inc

Diagnostics & Research
Healthcare

Prices are adjusted according to historical splits.

NeoGenomics Inc Stock Price

Vitals

Today's Low:
$13.62
Today's High:
$13.99
Open Price:
$13.77
52W Low:
$6
52W High:
$20.54
Prev. Close:
$13.89
Volume:
520297

Company Statistics

Market Cap.:
$1.77 billion
Book Value:
7.521
Revenue TTM:
$551.62 million
Operating Margin TTM:
-21.86%
Gross Profit TTM:
$187.90 million
Profit Margin:
-20.79%
Return on Assets TTM:
-4.32%
Return on Equity TTM:
-11.47%

Company Profile

NeoGenomics Inc had its IPO on 1999-11-02 under the ticker symbol NEO.

The company operates in the Healthcare sector and Diagnostics & Research industry. NeoGenomics Inc has a staff strength of 2,100 employees.

Stock update

Shares of NeoGenomics Inc opened at $13.77 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $13.62 - $13.99, and closed at $13.67.

This is a -1.58% slip from the previous day's closing price.

A total volume of 520,297 shares were traded at the close of the day’s session.

In the last one week, shares of NeoGenomics Inc have slipped by -9.89%.

NeoGenomics Inc's Key Ratios

NeoGenomics Inc has a market cap of $1.77 billion, indicating a price to book ratio of 1.3877 and a price to sales ratio of 2.7561.

In the last 12-months NeoGenomics Inc’s revenue was $551.62 million with a gross profit of $187.90 million and an EBITDA of $-48967000. The EBITDA ratio measures NeoGenomics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, NeoGenomics Inc’s operating margin was -21.86% while its return on assets stood at -4.32% with a return of equity of -11.47%.

In Q2, NeoGenomics Inc’s quarterly earnings growth was a positive 130.6% while revenue growth was a positive 17.5%.

NeoGenomics Inc’s PE and PEG Ratio

Forward PE
222.2222
Trailing PE
0
PEG
3.02

Its diluted EPS in the last 12-months stands at $-0.89 per share while it has a forward price to earnings multiple of 222.2222 and a PEG multiple of 3.02. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NeoGenomics Inc’s profitability.

NeoGenomics Inc stock is trading at a EV to sales ratio of 3.1681 and a EV to EBITDA ratio of -14.886. Its price to sales ratio in the trailing 12-months stood at 2.7561.

NeoGenomics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$1.70 billion
Total Liabilities
$94.85 million
Operating Cash Flow
$14.95 million
Capital Expenditure
$7.49 million
Dividend Payout Ratio
0%

NeoGenomics Inc ended 2024 with $1.70 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.70 billion while shareholder equity stood at $956.19 million.

NeoGenomics Inc ended 2024 with $28.81 million in deferred long-term liabilities, $94.85 million in other current liabilities, 127000.00 in common stock, $-214213000.00 in retained earnings and $522.77 million in goodwill. Its cash balance stood at $289.07 million and cash and short-term investments were $409.35 million. The company’s total short-term debt was $7,365,000 while long-term debt stood at $536.76 million.

NeoGenomics Inc’s total current assets stands at $584.72 million while long-term investments were $0 and short-term investments were $120.27 million. Its net receivables were $125.43 million compared to accounts payable of $87.48 million and inventory worth $24.95 million.

In 2024, NeoGenomics Inc's operating cash flow was $14.95 million while its capital expenditure stood at $7.49 million.

Comparatively, NeoGenomics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$13.67
52-Week High
$20.54
52-Week Low
$6
Analyst Target Price
$21.18

NeoGenomics Inc stock is currently trading at $13.67 per share. It touched a 52-week high of $20.54 and a 52-week low of $20.54. Analysts tracking the stock have a 12-month average target price of $21.18.

Its 50-day moving average was $15.43 and 200-day moving average was $14.76 The short ratio stood at 7.11 indicating a short percent outstanding of 0%.

Around 142% of the company’s stock are held by insiders while 9340% are held by institutions.

Frequently Asked Questions About NeoGenomics Inc

The stock symbol (also called stock or share ticker) of NeoGenomics Inc is NEO

The IPO of NeoGenomics Inc took place on 1999-11-02

Similar Industry Stocks (Diagnostics & Research)

Last Price
Chg
Chg%
$252.35
-19.7
-7.24%
$66.38
-1.24
-1.83%
$53.91
-3.19
-5.59%
$38.5
-1.47
-3.68%
$350.27
-0.15
-0.04%
$13.99
-0.01
-0.07%
JM Financial Limited (JMFINANCIL)
$85.02
-5.34
-5.91%
$1.41
0.06
+4.44%
$130.1
-3.05
-2.29%
Vimeo Inc (VMEO)
$3.92
0
0%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Address

9490 NeoGenomics Way, Fort Myers, FL, United States, 33912